Micah Pacifico
Nurse Practitioner · Danville, VANPI 1649819558
Payments from drug & device makers
Across 280 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$433
- Lilly USA, LLC$211
- Otsuka America Pharmaceutical, Inc.$178
- Biohaven Pharmaceutical Holding Company Ltd.$171
- Supernus Pharmaceuticals, Inc.$149
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 143 | $1,448 |
| Novo Nordisk | 27 | $433 |
| Lilly USA, LLC | 13 | $211 |
| Otsuka America Pharmaceutical, Inc. | 10 | $178 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $171 |
| Supernus Pharmaceuticals, Inc. | 9 | $149 |
| Amgen | 6 | $134 |
| Biohaven Pharmaceuticals, Inc. | 6 | $130 |
| Esperion Therapeutics, Inc. | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Amarin Pharma, Inc. | 5 | $71 |
| Aimmune Therapeutics, Inc. | 3 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Lundbeck LLC | 3 | $53 |
| Astellas Pharma US Inc | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Abbott | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Eisai Inc. | 2 | $26 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Advanced Oxygen Therapy Inc. | 2 | $23 |
| Alkermes, Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $16 |
| GSK | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Merck | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,717 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $114,005 |
| MounjaroTirzepatide | 34 | $48,073 |
| EliquisApixaban | 43 | $47,986 |
| JanuviaSitagliptin Phosphate | 36 | $45,667 |
| TrulicityDulaglutide | 24 | $34,157 |
| JardianceEmpagliflozin | 21 | $29,950 |
| FarxigaDapagliflozin Propanediol | 20 | $29,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,200 |
| XareltoRivaroxaban | 28 | $21,205 |
| LinzessLinaclotide | 14 | $10,202 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,775 |
| VascepaIcosapent Ethyl | 14 | $6,766 |
| Fenofibrate | 36 | $5,943 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,807 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $433 | $114,00568 claims |
| Lilly USA, LLCMounjaro, Trulicity | $211 | $82,23058 claims |
| PfizerEliquis | $12 | $47,98643 claims |
| MerckJanuvia | $12 | $45,66736 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $15 | $29,97551 claims |
| AbbVieLinzess | $1,448 | $10,20214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $74 | $4,78413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Danville
- Kim NesterDanville$8K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.